Overview

• Women's health company Hologic's fiscal Q4 rev grows 6.2% yr/yr, beating analyst expectations

• Non-GAAP EPS for fiscal Q4 beats consensus, increasing 11.9%

• Company to be acquired by Blackstone and TPG for up to $79 per share

Outlook

• Company is not providing guidance due to acquisition by Blackstone and TPG

Result Drivers

• DIAGNOSTICS GROWTH - Higher core U.S. molecular diagnostics sales drove diagnostics revenue growth, offset by lower COVID-19 assay sales and reduced sales in China

• BREAST HEALTH - Growth driven by strong interventional product sales and improved U.S. sales execution

• SURGICAL REVENUE - Increased sales of MyoSure and Fluent, and contributions from Gynesonics acquisition boosted surgical revenue

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 15 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for Hologic Inc is $75.50, about 2.1% above its October 31 closing price of $73.91

• The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nBw81t6qGa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)